These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37815278)

  • 1. Cost-Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for Patients With Heart Failure in China: A New Pillar in Our Pockets, but at What Price?
    Camilli M; Ballacci F; Giordano F; Minotti G
    J Cardiovasc Pharmacol; 2024 Jan; 83(1):43-45. PubMed ID: 37815278
    [No Abstract]   [Full Text] [Related]  

  • 2. Practical Considerations for the Use of Sodium-Glucose Co-Transporter 2 Inhibitors in Heart Failure.
    Honigberg MC; Vardeny O; Vaduganathan M
    Circ Heart Fail; 2020 Feb; 13(2):e006623. PubMed ID: 32059632
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis.
    Zhang N; Wang Y; Tse G; Korantzopoulos P; Letsas KP; Zhang Q; Li G; Lip GYH; Liu T
    Eur J Prev Cardiol; 2022 Feb; 28(17):1961-1973. PubMed ID: 34792124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: new guidelines hot off the press and directly into guidelines!
    Clark KAA
    Postgrad Med J; 2023 Sep; 99(1176):1052-1057. PubMed ID: 37001168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic Review of the Economic Evaluation of Sodium-Glucose Cotransporter-2 Inhibitors Used as Treatment in Patients with Heart Failure.
    Nam K; Cho DS; Kim H; Kwon B; Yoon Y; Park C; Kim ES; Youn JC; Park SK
    Clin Drug Investig; 2023 Jul; 43(7):463-474. PubMed ID: 37365452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Quadruple Therapy in Management of Heart Failure With Reduced Ejection Fraction in the United States.
    Yan BW; Spahillari A; Pandya A
    Circ Cardiovasc Qual Outcomes; 2023 Jun; 16(6):e009793. PubMed ID: 37278232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
    Kato ET; Silverman MG; Mosenzon O; Zelniker TA; Cahn A; Furtado RHM; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Bonaca MP; Ruff CT; Desai AS; Goto S; Johansson PA; Gause-Nilsson I; Johanson P; Langkilde AM; Raz I; Sabatine MS; Wiviott SD
    Circulation; 2019 May; 139(22):2528-2536. PubMed ID: 30882238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heart Failure and Diabetes: Perspective of a Dangerous Association.
    Favaloro LE; Ratto RD; Musso C
    Curr Hypertens Rev; 2021; 17(2):85-93. PubMed ID: 33823781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-glucose co-transporter 2 inhibitors for the prevention of heart failure in type 2 diabetes: A systematic review and meta-analysis.
    Yamani N; Usman MS; Akhtar T; Fatima K; Asmi N; Khan MS
    Eur J Prev Cardiol; 2020 Apr; 27(6):667-670. PubMed ID: 30966822
    [No Abstract]   [Full Text] [Related]  

  • 10. Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors.
    Evans M; Morgan AR; Yousef Z; Ellis G; Dashora U; Patel DC; Brown P; Hanif W; Townend JN; Kanumilli N; Moore J; Wilding JPH; Bain SC
    Drugs; 2021 Jul; 81(11):1243-1255. PubMed ID: 34160822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to Diuretics in Heart Failure: Any Role for Empagliflozin?
    Katsiki N; Triposkiadis F
    Curr Vasc Pharmacol; 2019; 17(4):421-424. PubMed ID: 30173648
    [No Abstract]   [Full Text] [Related]  

  • 12. Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.
    Berg DD; Wiviott SD; Scirica BM; Gurmu Y; Mosenzon O; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Johanson P; Johansson PA; Langkilde AM; Raz I; Braunwald E; Sabatine MS
    Circulation; 2019 Nov; 140(19):1569-1577. PubMed ID: 31474116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Ethics of Conducting Clinical Trials With Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: Is Placebo Assignment Justified in Patients With Comorbid Diabetes Mellitus and Heart Failure?
    Butler J; Anker SD
    Circulation; 2017 Oct; 136(16):1459-1461. PubMed ID: 29038205
    [No Abstract]   [Full Text] [Related]  

  • 14. Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus.
    Greene SJ; Butler J
    Circulation; 2019 Jan; 139(2):152-154. PubMed ID: 30615507
    [No Abstract]   [Full Text] [Related]  

  • 15. Diamonds in the Rough: The Incredible-but-True Story of Sodium Glucose Cotransporter 2 Inhibitors in Treatment of Heart Failure.
    Kosiborod M
    Circulation; 2021 Jan; 143(4):350-353. PubMed ID: 33493031
    [No Abstract]   [Full Text] [Related]  

  • 16. Diuretic effects of sodium-glucose cotransporter 2 inhibitor in patients with type 2 diabetes mellitus and heart failure.
    Takeuchi T; Dohi K; Omori T; Moriwaki K; Sato Y; Nakamori S; Fujimoto N; Fujii E; Yamada N; Ito M
    Int J Cardiol; 2015 Dec; 201():1-3. PubMed ID: 26278671
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus.
    Figtree GA; Rådholm K; Barrett TD; Perkovic V; Mahaffey KW; de Zeeuw D; Fulcher G; Matthews DR; Shaw W; Neal B
    Circulation; 2019 May; 139(22):2591-2593. PubMed ID: 30882240
    [No Abstract]   [Full Text] [Related]  

  • 18. Sodium glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: a systematic review and meta-analysis.
    Tsampasian V; Elghazaly H; Chattopadhyay R; Ali O; Corballis N; Chousou PA; Clark A; Garg P; Vassiliou VS
    Eur J Prev Cardiol; 2022 May; 29(6):e227-e229. PubMed ID: 34850881
    [No Abstract]   [Full Text] [Related]  

  • 19. Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Cardiovascular Outcomes in Patients with Diabetes Mellitus and Heart Failure.
    Hofer F; Kazem N; Richter B; Sulzgruber P; Schweitzer R; Pailer U; Hammer A; Koller L; Hengstenberg C; Niessner A
    Cardiovasc Drugs Ther; 2022 Jun; 36(3):497-504. PubMed ID: 34342791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Sodium-glucose cotransporter 2 inhibitors for the management of heart failure].
    Nouel A; Winter JL; Sepúlveda L
    Rev Med Chil; 2022 Dec; 150(12):1647-1654. PubMed ID: 37906786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.